HTDS receives follow up report and files with Pink Sheets

NewsGuard 100/100 Score

HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing. The filing called "Equity Capital Management Update On HTDS Report" can be found on Pink Sheets HTDS listing under the tab "Filings" or this direct link:>

The report, amongst other things addresses the following topics: Background of the company, Swine Flu (H1N1), Pink Sheets "Skull and Bones" to name a few.

The filing on Pink Sheets is timed to coincide and release at the same time as this news release shortly after 2:25 pm EST.

In other company news, as previously announced with the Canadian Pharmaceutical company continued interest and aspirations towards the cancer research and those IP rights of HTDS Slavica Bio Chem subsidiary will shortly be launching the cancer project and the cancer project web site www.mindupbioresearch.com. This, together with medical posters and other relevant information relating to the project will also be posted as a filing on Pink Sheets and on the company corporate web site www.htdsmedical.com shortly.

Source:

Hard to Treat Diseases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer